POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.

ABSTRACT:

Purpose

Recent studies have shown that 7% to 12% of endometrial cancers are ultramutated due to somatic mutation in the proofreading exonuclease domain of the DNA replicase POLE. Interestingly, these tumors have an excellent prognosis. In view of the emerging data linking mutation burden, immune response, and clinical outcome in cancer, we investigated whether POLE-mutant endometrial cancers showed evidence of increased immunogenicity.

Experimental design

We examined immune infiltration and activation according to tumor POLE proofreading mutation in a molecularly defined endometrial cancer cohort including 47 POLE-mutant tumors. We sought to confirm our results by analysis of RNAseq data from the TCGA endometrial cancer series and used the same series to examine whether diff

SUBMITTER: van Gool IC 

PROVIDER: S-EPMC4627582 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature